Send us Fan Mail In this episode of All Things Amyloid, we hear from renowned researcher Dr. Jeff Kelly from Scripps Research, pioneer in the field of amyloidosis. Current medical education on amyloid diseases is 25 years old and materially outdated, punctuated by rapid advancement in the last decade. Adapted from his video “The Systemic Amyloidoses vs Parkinson’s vs. Alzheimer’s” hear from Dr. Kelly, developer of ATTR amyloidosis drug Tafamidis, about the current biology and how amyloid diseases such as the Systemic Amyloidoses (ATTR and AL), Parkinson’s and Alzheimer's are today believed to be more similar than different. His video can be found in the Education Hub on Mackenzie’s Mission website. For an overview of amyloidosis, please see episode 2 (for clinicians) or episode 3 (for patients).
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_01Hi everyone. Welcome to the All Things Amyloid Podcast, where we feature patients, caregivers, and clinicians who discuss amyloidosis, a rare and incurable disease. Amyloidosis occurs when the body builds up abnormal amounts of misfolded amyloid protein, which can lead to serious and life-threatening outcomes. I'm your host, McKenzie, an amyloidosis patient and founder of Mackenzie's Mission. Our goal for this podcast is to raise awareness and share firsthand what it's like to live with this disease, to care for those affected by it, and to treat it.
SPEAKER_01We hope this leads to earlier diagnosis and start of treatment, which will improve patient lives. Over the past decade, research on amyloid protein diseases such as amyloidosis has rapidly advanced. This has strengthened our knowledge and laid a groundwork for developing treatments to ease the impact of these diseases. It has also revealed similarities previously unknown with other amyloid protein diseases such as Parkinson's and Alzheimer's. Adapted from his video, The Systemic Amyloidoses versus Parkinson's versus Alzheimer's.
SPEAKER_01Here, Dr. Jeff Kelly, a pioneer and leader in this space, provide an update to what's known and still unknown about amyloid diseases.
SPEAKER_00I'm Jeff Kelly at Scripps, and what I'd like to do today is to give you an overview of amyloid diseases. So let's just start out by saying that there are about 50 human amyloid diseases. And while there are differences between them, I would argue that there's a lot more similarities than differences. And what you should take home as a given is that protein aggregation destroys tissues that don't easily regenerate.
SPEAKER_00That's the main underpinning of human amyloid diseases. And there's a lot of segregation between the systemic amyloid diseases and the central nervous system disorders. But I hope I'll convince you by the end of this short presentation that this distinction may be more historic than useful, although you can draw your own conclusions on that. So the common amyloid diseases, of course, are Alzheimer's and Parkinson's.
SPEAKER_00All cases of Alzheimer's are associated with dementia. A fraction of Parkinson's patient cases are associated with dementia. And then, you know, the historically it was thought that transthyrocin and light chain amyloidosis were systemic amyloid diseases in the sense that they largely affected the periphery. But now we know for sure that transthyrocin amyloidosis evolves with time to be a central nervous system disease.
SPEAKER_00It still seems that light chain amyloidosis mostly affects the peripheral organs. Now the commonality amongst all human amyloid diseases is this cross beta sheet structure known as amyloid. So anytime you hear the word amyloid, you should think of protein structure. And it's a specific structure wherein one protein contributes to each ladder of an amyloid fibral, and the amyloid fibrils are very large.
SPEAKER_00So a folded protein is the size of a small town, whereas an amyloid fibral spans the distance from the east coast to the west coast. So they're huge structures in comparison to a folded protein, and they adopt this classic structure in an electron micrograph. And now cryo EM and X-ray structures have given us an atomic picture of what these structures look like.
SPEAKER_00Now remember, I said in the first slide that these are diseases whereby aggregates destroy tissues that don't easily regenerate. And the best examples of that are a beta and alpha-sinuclein associated with Alzheimer's and Parkinson's.
SPEAKER_00The notion is that these proteins then misassemble into all kinds of structures, including amyloid fibrils, which is the main pathological determinant of all of these diseases. But importantly, we do not know that amyloid is the main driver of the pathology. These other structures could contribute. And there's actually a lot of evidence in the literature, particularly in light chain amyloidosis, that these smaller structures are perhaps the main drivers of the pathology.
SPEAKER_00Moreover, there's evidence now from drug trials that if you can stop the transformation of newly synthesized proteins into these spectrum of aggregates, you can stop an amyloid disease from progressing without clearing the amyloid fibrils that are already present. So I just want to stress to you that there's a big question here with regards to what structures are the main drivers of amyloid disease.
SPEAKER_00And that's not resolved yet. Okay, so I've worked for decades on the transthyroetin amyloid diseases. And these diseases initially were thought to only affect peripheral nervous systems and peripheral organs. But now we know if we can protect these patients from organ disease and peripheral and autonomic nervous system disease without affecting the protein in the brain, ultimately they become central nervous system pathologies.
SPEAKER_00So how do these diseases work? Well, you have a normally folded protein, in this case, a tetamer, it has to dissociate and misfold, and that forms amyloid fibrils as well as all kinds of other structures. Initially, this process of aggregation destroys organ systems like the heart and the peripheral and autonomic nervous system. It generally affects the eye. And then, as I said, these initially peripheral diseases almost always progress to central nervous system pathology.
SPEAKER_00This is exactly what happens in Parkinson's disease. In Parkinson's, you first get gastrointestinal dysfunction for about a decade before you actually start to see brain pathology either manifesting as a movement disorder or as a dementia. So the drug that we develop for the transthyroetin amyloid diseases do not clear amyloid fibrils. This happens slowly, but not on the time scale of the clinical response.
SPEAKER_00What the drug does is it stabilizes newly synthesized protein and prevents its aggregation into the spectrum of non-native structures. And that's enough to stop the progression of the transthyroid amyloid diseases, no matter what the phenotype is, whether it's a cardiac phenotype or a neurological phenotype. And it probably prevents the onset of dementia as well, because we're fortunate in that typamidus gets into the brain.
SPEAKER_00And now there are many additional drugs that work for the transthyrin amyloid diseases that lower the concentration of transthyretin below the concentration that can aggregate. Now we learned that the transthirroin amyloid diseases, like Parkinson's, first affect the periphery and then the brain through these experiments where liver transplantation was used before the onset of Tefamidis to treat the hereditary TTR amyloid diseases that presented as a peripheral neuropathy.
SPEAKER_00So the point is that these patients are heterozygous. They have a mutation on one allele, wild type TTR on the other. So you generate mixed tetramers comprised of mutant and wild type subunits. And all the tetramers having mutant subunits come apart faster, they misfold faster, and therefore they put the patient at risk for an aggregation disease. So you can fix that by replacing the mutant-expressing liver by a liver that expresses only wild-type protein.
SPEAKER_00And this actually slows down the progression of the disease a lot. Now it's not done anymore because these individuals have fragile vasculature, and the rate of complications from liver transplant is about 10%. And so young, apparently healthy people die. And once that happens in a small town, nobody else wants a liver transplant, despite the fact that it's helpful. But importantly, what we learned from the survivors of this is that it does slow down disease progression, but it doesn't slow down the dementia onset, which occurs about 10 years after the peripheral symptoms.
SPEAKER_00And that's because transthyretin is synthesized in the brain. And the mutant protein and the wild type make these heterotetramers in the brain. And that ultimately leads to the demise of the parenchyma of the brain. And it's slower in the brain because the transthuretin concentration is about 25 times lower in the brain than it is in the periphery. And so, as I said, in the brain synthesizes transthyrocin through the choroid plexus, which secretes the protein into the cerebral spinal fluid, and its aggregation in the circulatory system of the brain causes the demise of the central nervous system.
SPEAKER_00Now, for light chain amyloidosis, as far as we know, the full-length light chain protein has to dissociate and probably in most cases it gets cleaved into smaller fragments that aggregate. And that destroys various organ systems. Now, because these light chains are fragments of antibodies, each patient has a different full-length light chain sequence.
SPEAKER_00And so the exact phenotype from patient to patient differs. And you really have to keep your eyes on this. I just talked to a patient this morning that had light chain amyloidosis with exclusively GI symptoms. More commonly, you have cardiac involvement or kidney involvement. And unfortunately, this disease is both a cancer and an amyloid disease. So the cancer component comes from the notion that you have clonoplasma cells that are expanded.
SPEAKER_00And these clonoplasma cells, instead of secreting antibodies, which is normally the case, they secrete these light chain full-length dimers, which can misfold and aggregate often, as I said, by virtue of proteolysis. So most of the time, these patients are treated by chemotherapy approaches or antibodies that kill the clonoplasma cells. And therefore, you lower the protein concentration dramatically that can lead that can form these aggregates, and which leads to the demise of tissues that don't easily regenerate.
SPEAKER_00So now regarding the central nervous system diseases, the principle is pretty simple. In order for the brain to work, the neurons have to undergo these massive communication networks. And once aggregates start to cause neurons to drop out of the central nervous system, then of course you start to have cognitive dysfunction. And in Alzheimer's disease, the cognitive dysfunction comes from neurons dropping out owing to A-beta plaques forming in the extracellular space and tau intracellular aggregates or amyloid forming within the axons of neurons.
SPEAKER_00And this kind of one-two punch from A-beta extracellular aggregation and tau intracellular aggregation causes neurons to start to die in the brain. And then with time, this causes the dementia and movement phenotypes of various um degenerative diseases. So, in particular, the notion was that the generation of the A beta peptide and its aggregation into amyloid plaques is the initial and important insult in Parkinson's disease.
SPEAKER_00And then later, the intracellular tau amyloid is what cause is memory dysfunction. Although now there's an antibody that was discovered by Lars Landfeld that blocks A-Beta aggregation and binds to amyloid fibrils, which in turn recruit microglial cells. And what these studies show is that even preventing A-beta aggregation and removing a beta amyloid fibrils slows the progression of Alzheimer's disease either by this sum of boxis score or this cognition score.
SPEAKER_00And this antibody very effectively clears amyloid fibrils. So this is very different than the way that the light chain and transthyroetin drugs work. There, the amyloid clearance is passive and very slow. Here, the antibody binds to the amyloid fibrils, recruit cells that clear the fibrils, namely microglia, and so the fibrils go away very quickly, as you can see from the patients on leucanomab versus the amyloid load of an individual receiving placebo.
SPEAKER_00I think this drug is going to turn out to be much more effective than what this graph indicates, which is about a 25% slowing in cognitive decline. This is not unlike what some of the initial results were for drugs in the diseases that affect the periphery, wherein you start treating patients earlier and earlier, and the drugs become more and more effective. So we shall see this very early days.
SPEAKER_00So I hope what I've shared with you today is that the conversion of a normally folded or intrinsically disordered protein into amyloid fibrils in most of these diseases affects both the periphery and the brain. And whether it affects the brain first and the periphery later, which happens in Alzheimer's disease, or it affects the periphery first and then the brain, which happens in transthyrocin amyloidosis and Parkinson's disease, depends in part on what the concentration of the protein is and many other environmental factors.
SPEAKER_00So be on the lookout for strange phenotypes in your patients, because not all of these patients present the same way. Sometimes in the transthyroetin amyloid diseases, the brain phenotypes appear first. And while I don't know of any examples of brain phenotype in light chain amyloidosis, it wouldn't shock me if somebody finds one someday. Okay, I hope I hope that it's very helpful.
SPEAKER_00Thank you.
SPEAKER_01The connection between amyloid diseases is narrowing, thanks to the research of biologists such as Dr. Kelly. As a result of these advancements in knowledge, new solutions are being developed to benefit both the diagnosis and treatment of amyloidosis, giving patients more hope than ever before. I hope you enjoyed today's episode. If you'd like to watch Dr. Kelly's video, please visit McKenzie's Mission Education Hub at mm713.org.
SPEAKER_01Thank you for listening to the All Things Amyloid Podcast. If you find our podcast informative, please follow and share it with others. If you want to learn more about the work we're doing at Mackenzie's Mission, please visit mm713.org. We'd also like to thank AstraZeneca Pharmaceuticals, Alexion Pharmaceuticals, Al Nylon Pharmaceuticals, and Bridge Biopharma for their sponsorship to help raise awareness about amyloidosis. We hope you stay tuned for future episode drops. Thanks for listening.
Send us Fan Mail Adapted from his video, in this episode of All Things Amyloid, Dr. Mat Maurer, cardiologist at Columbia University Irving Medical Center discusses the importance of developing a broad differential in...
Send us Fan Mail It’s that time of year for Medicare Open Enrollment - a season that impacts so many of our amyloidosis patients. I’ll be speaking with Ann Kayrish, an expert in this area and someone who worked for...
Send us Fan Mail Caregiving seems to be a universal role that many of us play at some time in our lives, whether we are ready for it or not. It may be for a child, parent, spouse, family member, or friend who is facing...
Send us Fan Mail It’s that time of year for Medicare Open Enrollment - a season that impacts so many of our amyloidosis patients. I’ll be speaking with Ann Kayrish, an expert in this area and someone who worked for...
Send us Fan Mail Amyloidosis patients often experience GI issues, both before and after diagnosis. The commonness of these symptoms can increase the difficulty of diagnosing amyloidosis. Adapted from her video...